CK-20在膀胱癌术后随访中的临床意义  

Clinical implications of the expression of cytokeratin-20 mRNA in the follow-up of patients with bladder carcinoma

作　　者：狄金明[1] 李庆文[1] 关超[1] 朱永献[1] 刘建民[1] 周文生[1] 胡永泉[1] 

机构地区：[1]安徽省蚌埠医学院附属医院泌尿外科,安徽蚌埠233004

出　　处：《现代泌尿外科杂志》2005年第2期69-71,共3页Journal of Modern Urology

基　　金：安徽省教育厅(人事厅)高校优秀青年教师科研项目(No.2000jq137);安徽省自然科学基金项目(No. 2001kj176)

摘　　要：目的　评估尿脱落细胞CK -20表达的检测在诊断膀胱癌复发中的价值及其临床意义。方法　对 60 例膀胱癌术后随访尿液标本进行CK -20标志物检测。分析参数包括肿瘤数目、大小、WHO分级及 CK- 20 mRNA标志物。结果　20 例复发者中 12例CK -20表达阳性(60%),且均为血尿标本; CK 20 表达检测诊断膀胱癌复发的敏感性、特异性及准确性分别为 60%、90%及80%; CK -20的表达与肿瘤分级间无明显相关性。结论　CK- 20 检测可以作为监测膀胱癌术后随访病人肿瘤复发的良好标记物。Objective To evaluate the significance and potential clinical implications of cytokeratin 20 (CK-20) expression in diagnosis of bladder cancer recurrence. Methods The expression of CK-20 mRNA was analysed in 60 urine samples from 42 patients with bladder carcinoma in postoperative follow-up. The analytic parameters included tumor size, number of tumor, tumor grade and CK-20 marker. Results Of the 20 cases whose bladder carcinoma recurred, the hematuria samples of 12 cases indicated positive CK-20 expression. The sensitivity, specificity and accuracy was 60%, 90% and 80% respectively with the analysis by RT-PCR for the expression of CK-20 mRNA in diagnosis of bladder cancer recurrence. No correlation was found between CK-20 expression and tumor grading. Conclusion The results indicate that CK-20 is a marker in diagnosis of bladder cancer recurrence in patients with bladder carcinoma in postoperative follow-up, especially in patients with hematuresis.

关 键 词：CK-20 膀胱癌 术后随访 表达 临床意义 癌复发 诊断 RNA 数目 特异性 

分 类 号：R737.14[医药卫生—肿瘤] R735[医药卫生—临床医学]